Prucalopride for the treatment of women with chronic constipation in whom standard laxative regimens have failed to provide adequate relief

M Pennant,* R Orlando, P Barton, S Bayliss, K Routh and C Meads

West Midlands Health Technology Assessment Collaboration, Department of Public Health, Epidemiology & Biostatistics, University of Birmingham, Birmingham, UK

*Corresponding author

Declared competing interests of authors: none
Abstract

This paper presents a summary of the evidence review group (ERG) report into the clinical effectiveness and cost-effectiveness of prucalopride for the treatment of women with chronic constipation in whom standard laxative regimens have failed to provide adequate relief. The ERG report is based on the manufacturer’s submission (MS) to the National Institute for Health and Clinical Excellence as part of the single technology appraisal process. In the submission, quality-of-life data [Patient Assessment of Constipation Quality of Life (PAC-QOL) and Patient Assessment of Constipation Symptoms (PAC-SYM) questionnaires] from trials of prucalopride were extrapolated to EQ-5D (European Quality of Life-5 Dimensions) data and used to inform effectiveness in an economic model. Response rates to prucalopride were derived from observed response rates in trials, defined as the proportion of patients achieving an average of three or more spontaneous complete bowel movements over the 4- or 12-week trial periods. Adult (18–64 years) and elderly (≥65 years) patients were considered separately in the model. Cost-effectiveness was determined from estimated improvements in EQ-5D and anticipated response rates, adjusted for baseline severity of chronic constipation. The ERG considered that the patients participating in these trials were not representative of those in the licensed indication. They were not all refractory to laxatives, and baseline EQ-5D scores showed a large spread in quality of life, with many patients experiencing little baseline dissatisfaction. The mapping of quality-of-life data from trials (PAC-QOL and PAC-SYM data) to EQ-5D was unclear and invalidated. The assumption of the long-term effectiveness and safety of prucalopride to 1 year was considered unjustified. There was no justification or sources given for coefficients used to predict effectiveness in the economic model, and no costs other than the cost of prucalopride were incorporated into the model. Owing to the many areas of uncertainty, particularly the effectiveness of prucalopride in the licensed patient group and its long-term effectiveness and safety, it was considered that the MS provided no evidence for whether prucalopride is effective or not in women with laxative-refractory chronic constipation. Further subgroup analysis of the actual patient group of interest may have better guided decision-making. However, long-term efficacy data, with validated estimates of quality of life incorporated in a well-founded model, would be important for an evidence-based judgement to be made.

Introduction

The National Institute for Health and Clinical Excellence (NICE) is an independent organisation within the NHS that is responsible for providing national guidance on the treatment and care of people using the NHS in England and Wales. One of responsibilities of NICE is to provide guidance to the NHS on the use of selected new and established health technologies, based on an appraisal of those technologies.

NICE’s single technology appraisal (STA) process is specifically designed for the appraisal of a single product, device or other technology, with a single indication, where most of the relevant evidence lies with one manufacturer or sponsor. Typically, it is used for new pharmaceutical products close to launch. The principal evidence for an STA is derived from a submission by the manufacturer/sponsor of the technology. In addition, a report reviewing the evidence submission is submitted by the evidence review group (ERG), an external organisation independent of the Institute. This paper presents a summary of the ERG report for the STA entitled Prucalopride for the treatment of women with chronic constipation in whom standard laxative regimens have failed to provide adequate relief.
**Description of the underlying health problem**

Chronic constipation may be idiopathic or secondary to other causes, such as drug use or neuromuscular conditions. This submission relates to patients with idiopathic chronic constipation that is not secondary to other causes and is a long-term disease. Rates of chronic constipation are higher in women than in men. Clinical trials of chronic constipation include ~90% women compared with ~10% men, and this may be representative of the relative prevalence in men and women.

The majority of patients with chronic constipation are managed in primary care. Non-pharmacological measures, such as dietary modification and exercise, are recommended in the first instance, and, where these fail, pharmacological measures (a range of laxative treatments) can be prescribed. However, for a small proportion of these patients, laxative measures used over a long period of time fail to bring about bowel movements. These patients, with chronic constipation that is refractory to laxative treatments, are the population for whom prucalopride is licensed and the patient group for which guidance was to be made.

Estimates for the prevalence of chronic constipation vary and it is difficult to make a precise estimate of the size of this patient group. Furthermore, it is difficult to assess, from within this group, the number of laxative-refractory patients for whom prucalopride may be indicated. In the manufacturer’s submission (MS), it was estimated that the total eligible adult patient group that might benefit from prucalopride in the UK is 363,000 (estimated from a 47 million UK adult population, assuming an average prevalence of chronic constipation of 7.7% and that 10% of patients are dissatisfied with, or refractory to, laxatives).

**Scope of the evidence review group report**

Prucalopride is licensed in women with chronic constipation who are refractory to laxative medications. The licence is for daily doses of 2 mg for adult patients (18–64 years) and 1 mg for elderly patients (≥65 years), and treatment costs are £2.13 and £1.38 per day, respectively.

In the submission, data from nine trials were used to inform the assessment of clinical effectiveness, and four of these trials, along with data from six additional trials, were used to inform the economic evaluation. In trials, response to treatment was measured in terms of the number of spontaneous complete bowel movements (SCBMs) and by using quality-of-life questionnaires. The main outcome measure was number of patients achieving a mean of three or more SCBMs over the first 4 and 12 weeks of trials. Patient Assessment of Constipation Quality of Life (PAC-QOL) and Patient Assessment of Constipation Symptoms (PAC-SYM) surveys, designed by manufacturers for use in the prucalopride trials, were used to obtain quality-of-life data and SF-36 questionnaires (Short Form questionnaire-36 items) were also used in some of the trials. Data from PAC-QOL and PAC-SYM questionnaires were mapped to give quality of life in terms of EQ-5D (European Quality of Life-5 Dimensions). Results from SF-36 questionnaires were used in the development of regression equations for the mapping of PAC-QOL and PAC-SYM data to EQ-5D.

For the economic model, quality of life gained by responders was estimated by one of eight different regression equations. Scenarios varied, depending on the definition of patient response (three or more SCBMs per week or an increase of one or more SCBM per week), whether patients had previously been on laxative treatment and whether constipation severity at baseline was considered. The cost of prucalopride was the only cost included in the model, and incremental cost-effectiveness ratios (ICERs) were presented separately for the adult and elderly populations.
The ERG report aimed to assess the extent to which the clinical effectiveness and cost-effectiveness parts of the MS covered the appropriate population, intervention, comparators and outcomes, and the extent to which information used in the economic model was valid and incorporated in an appropriate way.

**Methods**

The ERG report comprised a critical review of the evidence for the clinical effectiveness and cost-effectiveness of the technology, based upon the manufacturer’s/sponsor’s submission to NICE as part of the STA process.

Searches for studies of clinical effectiveness and cost-effectiveness were conducted. The clinical effectiveness part of the MS was assessed in terms of its coverage of relevant trials/studies, its relevance to the proposed drug indication and the quality of the presented data. The cost-effectiveness part of the submission was assessed in terms of the applicability of included data, the transparency in which model parameters were selected and the validity of assumptions used in the model.

Using the manufacturer’s economic model, the ERG performed additional analysis to investigate the effect of assuming that patients take prucalopride every day (instead of 220 days/year), incorporating an allowance for adverse events and reducing the estimated gain in quality of life.

**Results**

**Summary of submitted clinical evidence**

Results from nine trials were presented: three ‘pivotal’ trials,3–5 one trial in elderly patients,6 one re-treatment study,7 one trial in patients with opioid-induced chronic constipation8 and three long-term open-label studies.9–11 Results for the three ‘pivotal’ trials3–5 (pooled by the ERG) and the trial in elderly patients6 are given in Table 1.

The open-label studies, conducted in patients from a mixture of different trials, showed that satisfaction with treatment in patients remaining in the study remained constant over the first year of treatment. However, 60% of patients had dropped out at 1 year (17% insufficient response, 8% adverse events). The re-treatment study showed that treatment with prucalopride in patients remaining in the study was just as effective. However, only data for 4 mg prucalopride were presented in the submission and only data from patients who did not drop out between study periods were used for the analysis. The trial in patients with opioid-induced chronic constipation was not relevant to this submission so was not assessed by the ERG.

**Summary of submitted cost-effectiveness evidence**

A cost-effectiveness model included costs for only prucalopride and no alternative treatment costs were incorporated. The quoted costs per responder were based on 292 days’ treatment (80% ‘compliance’) and estimated at £622 per adult patient and £402 per elderly patient per year on treatment. The base-case model predicted quality-adjusted life-year gains per responder of 0.0369 [standard deviation (SD) 0.0450] and 0.0342 (SD 0.1495) for adult and elderly patients, respectively, giving ICERs of £16,800 and £11,700, respectively.
Commentary on the robustness of submitted evidence

The submitted evidence was not considered to be robust and many factors remained unclear even after requests for clarification. There was poor transparency around the submission and the modelling process. The main specific areas for concern were:

1. The trials on which data for this submission were based were not conducted in patients with chronic constipation that was refractory to laxatives. This was evidenced in a number of ways:
   i. Around 17.0% of patients in pivotal trials had found their previous treatment adequate.
   ii. Bisacodyl, a laxative, was used as a rescue medication in the trials and, on average, it induced one or more bowel movements per week in study participants.
   iii. Baseline EQ-5D scores (higher score, less severe) for adult (18–65 years) and elderly (≥65 years) patient data (Figure 1) suggest that these were not homogeneous patient groups and that many patients were not representative of the severe cases for whom prucalopride is licensed.

### TABLE 1 Pooled results for pivotal trials and results for the trial in elderly patients

<table>
<thead>
<tr>
<th></th>
<th>Prucalopride</th>
<th>Placebo</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Proportion of patients with mean of three or more SCBMs/week: % (n/N)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pivotal trials</td>
<td>23.8 (151/635)</td>
<td>11.4 (73/640)</td>
</tr>
<tr>
<td>Elderly</td>
<td>39.5 (30/76)</td>
<td>20.0 (14/70)</td>
</tr>
<tr>
<td><strong>Proportion of patients with average increase of one or more SCBMs/week: % (n/N)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pivotal trials</td>
<td>43.2 (264/612)</td>
<td>24.6 (155/630)</td>
</tr>
<tr>
<td>Elderly</td>
<td>61.1 (44/72)</td>
<td>33.8 (22/65)</td>
</tr>
<tr>
<td><strong>Average number of SCBM/week: mean (mean change from baseline)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pivotal trials</td>
<td>1.9 (1.5)</td>
<td>1.2 (0.7)</td>
</tr>
<tr>
<td>Elderly</td>
<td>2.7 (1.9)</td>
<td>1.7 (0.6)</td>
</tr>
<tr>
<td><strong>Overall PAC-SYM symptoms score: mean (mean change from baseline)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pivotal trials</td>
<td>1.33 (–0.69)</td>
<td>1.57 (–0.42)</td>
</tr>
<tr>
<td>Elderly</td>
<td>0.88 (–0.53)</td>
<td>1.22 (–0.23)</td>
</tr>
<tr>
<td><strong>Overall PAC-QOL score: mean (mean change from baseline)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pivotal trials</td>
<td>1.33 (–0.77)</td>
<td>1.68 (–0.44)</td>
</tr>
<tr>
<td>Elderly</td>
<td>0.95 (–0.53)</td>
<td>1.26 (–0.20)</td>
</tr>
<tr>
<td><strong>SF-36 score: mean (mean change from baseline)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pivotal trials</td>
<td>48.2 (2.5)</td>
<td>47.5 (1.9)</td>
</tr>
<tr>
<td>Elderly</td>
<td>Not measured</td>
<td>Not measured</td>
</tr>
</tbody>
</table>

PAC-QOL, Patient Assessment of Constipation Quality of Life; PAC-SYM, Patient Assessment of Constipation Symptoms; SCBM, spontaneous complete bowel movement; SF-36, Short Form questionnaire-36 items.

a. Pivotal trials: >18 years old, 12-week data, 2 mg of prucalopride.
b. Elderly patient trial: >65 years old, 4-week data, 1 mg of prucalopride.
2. The extrapolation of data from PAC-QOL and PAC-SYM trial surveys to EQ-5Q data used in the economic model was unclear.

3. The model assumption that the relative advantage in quality of life in patients treated with prucalopride at the end of study follow-up (4 or 12 weeks) is maintained at 52 weeks is inappropriate owing to:
   i. The high attrition in follow-up studies (> 60%). Patients remaining in the trial were likely to have been those who were relatively more satisfied.
   ii. Decreases in efficacy from the periods 1–4 weeks compared with 1–12 weeks in pivotal trials suggest that effectiveness was likely to decrease with time.

**FIGURE 1** Baseline EQ-5D scores for (a) adult (18–64 years) and (b) elderly (≥65 years) patient data used in the economic model.
iii. The lack of comparative data. If relative quality of life is to be compared, follow-up data in the placebo group would also be required.

iv. Patients in long-term follow-up trials included patients who were not refractory to laxatives, and patient groups were mixtures of adult/elderly patients and patients with opioid-induced constipation.

v. This assumption is not tested in the manufacturer's model. In order to test the effect of a reduction in quality-of-life gain over time, the ERG re-ran the model, considering a decrease in change in EQ-5D of 25%, 50% and 75% and the ICER was substantially increased.

4. There was no justification or explanation for the parameters used in the economic model. It was not possible to link the data that populated the model to the clinical trials. There was no way of discerning whether coefficients used in the model truly represented treatment effects.

5. No costs, other than the cost of prucalopride, were incorporated into the economic model.

6. In the model, the average use of prucalopride in responders has been assumed to be for 220 days per year but this assumption may not be justified. The ERG re-ran the model considering that all responders take treatment for the full year (365 days), and this made a substantial increase in the ICER.

7. No specific allowance was made for withdrawal from treatment at any time after 4 weeks.

8. Adverse events were not included in the model.

The population targeted in the scope of this technology appraisal is unlikely to be the same as that used to populate the economic model. Overall, it was felt that this submission provided no proper evidence on whether or not prucalopride is likely to be cost-effective compared with other treatment strategies in patients in the licensed indication.

Conclusions

Owing to the many areas of uncertainty, particularly the effectiveness of prucalopride in the licensed patient group and its long-term effectiveness and safety, it was considered that the MS provided no evidence for whether prucalopride is effective or not in women with laxative-refractory chronic constipation. Further subgroup analysis of the actual patient group of interest may have better guided decision-making. However, long-term efficacy data, with validated estimates of quality of life incorporated in a well-founded model, would be important for an evidence-based judgement to be made.

Summary of NICE guidance issued as a result of the STA

1.1 Prucalopride is recommended as an option for the treatment of chronic constipation only in women for whom treatment with at least two laxatives from different classes at the highest tolerated recommended doses for at least 6 months has failed to provide adequate relief and invasive treatment for constipation is being considered.

1.2 If treatment with prucalopride is not effective after 4 weeks, the patient should be re-examined and the benefit of continuing treatment reconsidered.

1.3 Prucalopride should only be prescribed by a clinician with experience of treating chronic constipation, who has supervised the woman's previous courses of laxative treatments specified in 1.
Key references


